Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-03-26

AUTHORS

Bjorn Nashan, Peter Schemmer, Felix Braun, Markus Dworak, Peter Wimmer, Hans Schlitt

ABSTRACT

BACKGROUND: Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients. However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity, de novo malignancies, recurrence of hepatitis C viral (HCV) infection and hepatocellular carcinoma. Several studies have shown that everolimus has the potential to provide protection against viral replication, malignancy, and progression of fibrosis, as well as preventing nephrotoxicity by facilitating calcineurin inhibitor reduction without compromising efficacy. The Hephaistos study evaluates the beneficial effects of early initiation of everolimus in de novo liver transplant recipients. METHODS/DESIGN: Hephaistos is an ongoing 12-month, multi-center, open-label, controlled study aiming to enroll 330 de novo liver transplant recipients from 15 centers across Germany. Patients are randomized in a 1:1 ratio (7-21 days post-transplantation) to receive everolimus (trough levels 3-8 ng/mL) with reduced tacrolimus (trough levels <5 ng/mL), or standard tacrolimus (trough levels 6-10 ng/mL) after entering a run-in period (3-5 days post-transplantation). In the run-in period, patients are treated with induction therapy, mycophenolate mofetil, tacrolimus, and corticosteroids according to local practice. Randomization is stratified by HCV status and model of end-stage liver disease scores at transplantation. The primary objective of the study is to exhibit superior renal function (estimated glomerular filtration rate assessed by the Modification of Diet in Renal Disease (MDRD)-4 formula) with everolimus plus reduced tacrolimus compared to standard tacrolimus at Month 12. Other objectives are: to assess the incidence of treated biopsy-proven acute rejection, graft loss, or death; the incidences of components of the composite efficacy endpoint; renal function via estimated glomerular filtration rate using various formulae (MDRD-4, Nankivell, Cockcroft-Gault, chronic kidney disease epidemiology collaboration and Hoek formulae); the incidence of proteinuria; the incidence of adverse events and serious adverse events; the incidence and severity of cytomegalovirus and HCV infections and HCV-related fibrosis. DISCUSSION: This study aims to demonstrate superior renal function, comparable efficacy, and safety in de novo liver transplant recipients receiving everolimus with reduced tacrolimus compared with standard tacrolimus. This study also evaluates the antiviral benefit by early initiation of everolimus. TRIAL REGISTRATION: NCT01551212 . More... »

PAGES

118

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-015-0626-0

DOI

http://dx.doi.org/10.1186/s13063-015-0626-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023495111

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25873064


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcineurin Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glomerular Filtration Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft Rejection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Failure, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TOR Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tacrolimus", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hepatobiliary Surgery and Visceral Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.13648.38", 
          "name": [
            "Department of Hepatobiliary Surgery and Visceral Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nashan", 
        "givenName": "Bjorn", 
        "id": "sg:person.0632135117.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632135117.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5253.1", 
          "name": [
            "Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schemmer", 
        "givenName": "Peter", 
        "id": "sg:person.01000165004.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000165004.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery and Thoracic Surgery, University Hospital Schleswig, Kiel, Holstein Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of General Surgery and Thoracic Surgery, University Hospital Schleswig, Kiel, Holstein Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Braun", 
        "givenName": "Felix", 
        "id": "sg:person.01104611045.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104611045.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dworak", 
        "givenName": "Markus", 
        "id": "sg:person.01036413063.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036413063.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wimmer", 
        "givenName": "Peter", 
        "id": "sg:person.0655576113.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655576113.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, University Hospital Regensburg, Regensburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411941.8", 
          "name": [
            "Department of Surgery, University Hospital Regensburg, Regensburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schlitt", 
        "givenName": "Hans", 
        "id": "sg:person.010361144542.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010361144542.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00423-011-0766-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035441515", 
          "https://doi.org/10.1007/s00423-011-0766-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2047-1440-3-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046656925", 
          "https://doi.org/10.1186/2047-1440-3-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00268-014-2756-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011715166", 
          "https://doi.org/10.1007/s00268-014-2756-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-03-26", 
    "datePublishedReg": "2015-03-26", 
    "description": "BACKGROUND: Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients. However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity, de novo malignancies, recurrence of hepatitis C viral (HCV) infection and hepatocellular carcinoma. Several studies have shown that everolimus has the potential to provide protection against viral replication, malignancy, and progression of fibrosis, as well as preventing nephrotoxicity by facilitating calcineurin inhibitor reduction without compromising efficacy. The Hephaistos study evaluates the beneficial effects of early initiation of everolimus in de novo liver transplant recipients.\nMETHODS/DESIGN: Hephaistos is an ongoing 12-month, multi-center, open-label, controlled study aiming to enroll 330 de novo liver transplant recipients from 15 centers across Germany. Patients are randomized in a 1:1 ratio (7-21\u00a0days post-transplantation) to receive everolimus (trough levels 3-8\u00a0ng/mL) with reduced tacrolimus (trough levels <5\u00a0ng/mL), or standard tacrolimus (trough levels 6-10\u00a0ng/mL) after entering a run-in period (3-5\u00a0days post-transplantation). In the run-in period, patients are treated with induction therapy, mycophenolate mofetil, tacrolimus, and corticosteroids according to local practice. Randomization is stratified by HCV status and model of end-stage liver disease scores at transplantation. The primary objective of the study is to exhibit superior renal function (estimated glomerular filtration rate assessed by the Modification of Diet in Renal Disease (MDRD)-4 formula) with everolimus plus reduced tacrolimus compared to standard tacrolimus at Month 12. Other objectives are: to assess the incidence of treated biopsy-proven acute rejection, graft loss, or death; the incidences of components of the composite efficacy endpoint; renal function via estimated glomerular filtration rate using various formulae (MDRD-4, Nankivell, Cockcroft-Gault, chronic kidney disease epidemiology collaboration and Hoek formulae); the incidence of proteinuria; the incidence of adverse events and serious adverse events; the incidence and severity of cytomegalovirus and HCV infections and HCV-related fibrosis.\nDISCUSSION: This study aims to demonstrate superior renal function, comparable efficacy, and safety in de novo liver transplant recipients receiving everolimus with reduced tacrolimus compared with standard tacrolimus. This study also evaluates the antiviral benefit by early initiation of everolimus.\nTRIAL REGISTRATION: NCT01551212 .", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13063-015-0626-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "de novo liver transplant recipients", 
      "novo liver transplant recipients", 
      "liver transplant recipients", 
      "superior renal function", 
      "transplant recipients", 
      "renal function", 
      "standard tacrolimus", 
      "early initiation", 
      "adverse events", 
      "calcineurin inhibitors", 
      "end-stage liver disease (MELD) score", 
      "biopsy-proven acute rejection", 
      "hepatitis C viral infection", 
      "de novo malignancies", 
      "calcineurin inhibitor reduction", 
      "incidence of components", 
      "composite efficacy endpoint", 
      "incidence of proteinuria", 
      "Liver Disease score", 
      "serious adverse events", 
      "chronic renal failure", 
      "glomerular filtration rate", 
      "progression of fibrosis", 
      "long-term use", 
      "novo malignancies", 
      "reduced tacrolimus", 
      "tacrolimus reduction", 
      "induction therapy", 
      "HCV status", 
      "acute rejection", 
      "graft loss", 
      "HCV infection", 
      "mycophenolate mofetil", 
      "efficacy endpoint", 
      "renal failure", 
      "month 12", 
      "filtration rate", 
      "comparable efficacy", 
      "hepatocellular carcinoma", 
      "tacrolimus", 
      "high risk", 
      "everolimus", 
      "disease score", 
      "antiviral benefit", 
      "viral infection", 
      "survival rate", 
      "viral replication", 
      "incidence", 
      "beneficial effects", 
      "recipients", 
      "inhibitor reduction", 
      "efficacy", 
      "patients", 
      "malignancy", 
      "fibrosis", 
      "infection", 
      "primary objective", 
      "inhibitors", 
      "initiation", 
      "safety", 
      "mofetil", 
      "corticosteroids", 
      "proteinuria", 
      "HCV", 
      "nephrotoxicity", 
      "transplantation", 
      "recurrence", 
      "carcinoma", 
      "therapy", 
      "neurotoxicity", 
      "cytomegalovirus", 
      "study", 
      "progression", 
      "trials", 
      "endpoint", 
      "severity", 
      "death", 
      "period", 
      "risk", 
      "scores", 
      "randomization", 
      "rate", 
      "reduction", 
      "events", 
      "status", 
      "local practices", 
      "function", 
      "failure", 
      "objective", 
      "rejection", 
      "replication", 
      "center", 
      "protocol", 
      "benefits", 
      "loss", 
      "effect", 
      "protection", 
      "use", 
      "practice", 
      "ratio", 
      "potential", 
      "introduction", 
      "components", 
      "Germany", 
      "model", 
      "run", 
      "formula", 
      "evolution", 
      "Hephaistos", 
      "C viral (HCV) infection", 
      "Hephaistos study", 
      "severity of cytomegalovirus", 
      "NCT01551212"
    ], 
    "name": "Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial", 
    "pagination": "118", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023495111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-015-0626-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25873064"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-015-0626-0", 
      "https://app.dimensions.ai/details/publication/pub.1023495111"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_659.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13063-015-0626-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-015-0626-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-015-0626-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-015-0626-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-015-0626-0'


 

This table displays all metadata directly associated to this object as RDF triples.

302 TRIPLES      22 PREDICATES      159 URIs      148 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-015-0626-0 schema:about N0fb545bbe2c34541bb318022f2417bfc
2 N11ff252639a1443ca412883a0d6b6d1f
3 N2b5ac8c15883460693b1f965b851d14a
4 N3879d84e61d0462d9a362d3dbd845f25
5 N4c86d15ac1f74a299a60b113dc1ca65f
6 N6973b486b71941698a8fa488f3f42075
7 N854a9abb91f04f41bdc768a91bb7074b
8 N9a326cdd183243a18a204884e20cb569
9 N9be21c2f942647c99b58f6ce2ba7784f
10 N9f4f77b74eaf4838983f50e84ba2a260
11 Na4927f18b750456a853b851810e4e1f0
12 Nc8e6c14cf3754da9912c31a380e3d6e4
13 Nd5d8155a0b394ba1bb6c64cae4551fe9
14 Ndec3a87a447440709243f9b4f876f940
15 Ndf953a977abd4eb4a7729dad7e32e3cc
16 Ne1e7df93712f49eba039970518aebb63
17 Nf078b3f6034d4e198312a77f0d8caaf7
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Nf4619fcd14fd47c19b3f28841059f309
21 schema:citation sg:pub.10.1007/s00268-014-2756-z
22 sg:pub.10.1007/s00423-011-0766-y
23 sg:pub.10.1186/2047-1440-3-5
24 schema:datePublished 2015-03-26
25 schema:datePublishedReg 2015-03-26
26 schema:description BACKGROUND: Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients. However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity, de novo malignancies, recurrence of hepatitis C viral (HCV) infection and hepatocellular carcinoma. Several studies have shown that everolimus has the potential to provide protection against viral replication, malignancy, and progression of fibrosis, as well as preventing nephrotoxicity by facilitating calcineurin inhibitor reduction without compromising efficacy. The Hephaistos study evaluates the beneficial effects of early initiation of everolimus in de novo liver transplant recipients. METHODS/DESIGN: Hephaistos is an ongoing 12-month, multi-center, open-label, controlled study aiming to enroll 330 de novo liver transplant recipients from 15 centers across Germany. Patients are randomized in a 1:1 ratio (7-21 days post-transplantation) to receive everolimus (trough levels 3-8 ng/mL) with reduced tacrolimus (trough levels <5 ng/mL), or standard tacrolimus (trough levels 6-10 ng/mL) after entering a run-in period (3-5 days post-transplantation). In the run-in period, patients are treated with induction therapy, mycophenolate mofetil, tacrolimus, and corticosteroids according to local practice. Randomization is stratified by HCV status and model of end-stage liver disease scores at transplantation. The primary objective of the study is to exhibit superior renal function (estimated glomerular filtration rate assessed by the Modification of Diet in Renal Disease (MDRD)-4 formula) with everolimus plus reduced tacrolimus compared to standard tacrolimus at Month 12. Other objectives are: to assess the incidence of treated biopsy-proven acute rejection, graft loss, or death; the incidences of components of the composite efficacy endpoint; renal function via estimated glomerular filtration rate using various formulae (MDRD-4, Nankivell, Cockcroft-Gault, chronic kidney disease epidemiology collaboration and Hoek formulae); the incidence of proteinuria; the incidence of adverse events and serious adverse events; the incidence and severity of cytomegalovirus and HCV infections and HCV-related fibrosis. DISCUSSION: This study aims to demonstrate superior renal function, comparable efficacy, and safety in de novo liver transplant recipients receiving everolimus with reduced tacrolimus compared with standard tacrolimus. This study also evaluates the antiviral benefit by early initiation of everolimus. TRIAL REGISTRATION: NCT01551212 .
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N2b25a0e910c74697b36021767c961677
31 N64406f4ac21a424fb52d2e9ced5f0acc
32 sg:journal.1297400
33 schema:keywords C viral (HCV) infection
34 Germany
35 HCV
36 HCV infection
37 HCV status
38 Hephaistos
39 Hephaistos study
40 Liver Disease score
41 NCT01551212
42 acute rejection
43 adverse events
44 antiviral benefit
45 beneficial effects
46 benefits
47 biopsy-proven acute rejection
48 calcineurin inhibitor reduction
49 calcineurin inhibitors
50 carcinoma
51 center
52 chronic renal failure
53 comparable efficacy
54 components
55 composite efficacy endpoint
56 corticosteroids
57 cytomegalovirus
58 de novo liver transplant recipients
59 de novo malignancies
60 death
61 disease score
62 early initiation
63 effect
64 efficacy
65 efficacy endpoint
66 end-stage liver disease (MELD) score
67 endpoint
68 events
69 everolimus
70 evolution
71 failure
72 fibrosis
73 filtration rate
74 formula
75 function
76 glomerular filtration rate
77 graft loss
78 hepatitis C viral infection
79 hepatocellular carcinoma
80 high risk
81 incidence
82 incidence of components
83 incidence of proteinuria
84 induction therapy
85 infection
86 inhibitor reduction
87 inhibitors
88 initiation
89 introduction
90 liver transplant recipients
91 local practices
92 long-term use
93 loss
94 malignancy
95 model
96 mofetil
97 month 12
98 mycophenolate mofetil
99 nephrotoxicity
100 neurotoxicity
101 novo liver transplant recipients
102 novo malignancies
103 objective
104 patients
105 period
106 potential
107 practice
108 primary objective
109 progression
110 progression of fibrosis
111 protection
112 proteinuria
113 protocol
114 randomization
115 rate
116 ratio
117 recipients
118 recurrence
119 reduced tacrolimus
120 reduction
121 rejection
122 renal failure
123 renal function
124 replication
125 risk
126 run
127 safety
128 scores
129 serious adverse events
130 severity
131 severity of cytomegalovirus
132 standard tacrolimus
133 status
134 study
135 superior renal function
136 survival rate
137 tacrolimus
138 tacrolimus reduction
139 therapy
140 transplant recipients
141 transplantation
142 trials
143 use
144 viral infection
145 viral replication
146 schema:name Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial
147 schema:pagination 118
148 schema:productId N390625ec3fa044dc8d6f5f89782de55c
149 N51cf7d1f62a843948adaab0a2820bfc9
150 Na201d1e1337e4fb0bc2719fe0ad62475
151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023495111
152 https://doi.org/10.1186/s13063-015-0626-0
153 schema:sdDatePublished 2021-12-01T19:32
154 schema:sdLicense https://scigraph.springernature.com/explorer/license/
155 schema:sdPublisher N9f29df5fa09e4a208be8c66fb4fdca24
156 schema:url https://doi.org/10.1186/s13063-015-0626-0
157 sgo:license sg:explorer/license/
158 sgo:sdDataset articles
159 rdf:type schema:ScholarlyArticle
160 N0d19660fb1f3481aa707f64066d77dac rdf:first sg:person.01036413063.23
161 rdf:rest N4c9b88b795a54c3697a2457610199936
162 N0fb545bbe2c34541bb318022f2417bfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Middle Aged
164 rdf:type schema:DefinedTerm
165 N11ff252639a1443ca412883a0d6b6d1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Liver Transplantation
167 rdf:type schema:DefinedTerm
168 N2b25a0e910c74697b36021767c961677 schema:issueNumber 1
169 rdf:type schema:PublicationIssue
170 N2b5ac8c15883460693b1f965b851d14a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Calcineurin Inhibitors
172 rdf:type schema:DefinedTerm
173 N3879d84e61d0462d9a362d3dbd845f25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Drug Therapy, Combination
175 rdf:type schema:DefinedTerm
176 N390625ec3fa044dc8d6f5f89782de55c schema:name pubmed_id
177 schema:value 25873064
178 rdf:type schema:PropertyValue
179 N4c86d15ac1f74a299a60b113dc1ca65f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Immunosuppressive Agents
181 rdf:type schema:DefinedTerm
182 N4c9b88b795a54c3697a2457610199936 rdf:first sg:person.0655576113.43
183 rdf:rest Nc606ee9114ee4d1ca5f46b03d4a2e187
184 N51cf7d1f62a843948adaab0a2820bfc9 schema:name doi
185 schema:value 10.1186/s13063-015-0626-0
186 rdf:type schema:PropertyValue
187 N64406f4ac21a424fb52d2e9ced5f0acc schema:volumeNumber 16
188 rdf:type schema:PublicationVolume
189 N6973b486b71941698a8fa488f3f42075 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Research Design
191 rdf:type schema:DefinedTerm
192 N7531b56bbda74c54ae07490d48bd176c rdf:first sg:person.01104611045.10
193 rdf:rest N0d19660fb1f3481aa707f64066d77dac
194 N854a9abb91f04f41bdc768a91bb7074b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name TOR Serine-Threonine Kinases
196 rdf:type schema:DefinedTerm
197 N9a326cdd183243a18a204884e20cb569 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Humans
199 rdf:type schema:DefinedTerm
200 N9be21c2f942647c99b58f6ce2ba7784f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Sirolimus
202 rdf:type schema:DefinedTerm
203 N9f29df5fa09e4a208be8c66fb4fdca24 schema:name Springer Nature - SN SciGraph project
204 rdf:type schema:Organization
205 N9f4f77b74eaf4838983f50e84ba2a260 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Adult
207 rdf:type schema:DefinedTerm
208 Na201d1e1337e4fb0bc2719fe0ad62475 schema:name dimensions_id
209 schema:value pub.1023495111
210 rdf:type schema:PropertyValue
211 Na4927f18b750456a853b851810e4e1f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Kidney
213 rdf:type schema:DefinedTerm
214 Nc606ee9114ee4d1ca5f46b03d4a2e187 rdf:first sg:person.010361144542.53
215 rdf:rest rdf:nil
216 Nc8e6c14cf3754da9912c31a380e3d6e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Clinical Protocols
218 rdf:type schema:DefinedTerm
219 Nd5d8155a0b394ba1bb6c64cae4551fe9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Glomerular Filtration Rate
221 rdf:type schema:DefinedTerm
222 Ndec3a87a447440709243f9b4f876f940 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Everolimus
224 rdf:type schema:DefinedTerm
225 Ndf953a977abd4eb4a7729dad7e32e3cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Tacrolimus
227 rdf:type schema:DefinedTerm
228 Ne1e7df93712f49eba039970518aebb63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
229 schema:name Graft Rejection
230 rdf:type schema:DefinedTerm
231 Nf078b3f6034d4e198312a77f0d8caaf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
232 schema:name Kidney Failure, Chronic
233 rdf:type schema:DefinedTerm
234 Nf4619fcd14fd47c19b3f28841059f309 rdf:first sg:person.0632135117.08
235 rdf:rest Nffb56279ed6749e69831ae917b301e4c
236 Nffb56279ed6749e69831ae917b301e4c rdf:first sg:person.01000165004.34
237 rdf:rest N7531b56bbda74c54ae07490d48bd176c
238 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
239 schema:name Medical and Health Sciences
240 rdf:type schema:DefinedTerm
241 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
242 schema:name Clinical Sciences
243 rdf:type schema:DefinedTerm
244 sg:journal.1297400 schema:issn 1468-6708
245 1745-6215
246 schema:name Trials
247 schema:publisher Springer Nature
248 rdf:type schema:Periodical
249 sg:person.01000165004.34 schema:affiliation grid-institutes:grid.5253.1
250 schema:familyName Schemmer
251 schema:givenName Peter
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000165004.34
253 rdf:type schema:Person
254 sg:person.010361144542.53 schema:affiliation grid-institutes:grid.411941.8
255 schema:familyName Schlitt
256 schema:givenName Hans
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010361144542.53
258 rdf:type schema:Person
259 sg:person.01036413063.23 schema:affiliation grid-institutes:grid.467675.1
260 schema:familyName Dworak
261 schema:givenName Markus
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036413063.23
263 rdf:type schema:Person
264 sg:person.01104611045.10 schema:affiliation grid-institutes:None
265 schema:familyName Braun
266 schema:givenName Felix
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104611045.10
268 rdf:type schema:Person
269 sg:person.0632135117.08 schema:affiliation grid-institutes:grid.13648.38
270 schema:familyName Nashan
271 schema:givenName Bjorn
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632135117.08
273 rdf:type schema:Person
274 sg:person.0655576113.43 schema:affiliation grid-institutes:grid.467675.1
275 schema:familyName Wimmer
276 schema:givenName Peter
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655576113.43
278 rdf:type schema:Person
279 sg:pub.10.1007/s00268-014-2756-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1011715166
280 https://doi.org/10.1007/s00268-014-2756-z
281 rdf:type schema:CreativeWork
282 sg:pub.10.1007/s00423-011-0766-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1035441515
283 https://doi.org/10.1007/s00423-011-0766-y
284 rdf:type schema:CreativeWork
285 sg:pub.10.1186/2047-1440-3-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046656925
286 https://doi.org/10.1186/2047-1440-3-5
287 rdf:type schema:CreativeWork
288 grid-institutes:None schema:alternateName Department of General Surgery and Thoracic Surgery, University Hospital Schleswig, Kiel, Holstein Germany
289 schema:name Department of General Surgery and Thoracic Surgery, University Hospital Schleswig, Kiel, Holstein Germany
290 rdf:type schema:Organization
291 grid-institutes:grid.13648.38 schema:alternateName Department of Hepatobiliary Surgery and Visceral Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
292 schema:name Department of Hepatobiliary Surgery and Visceral Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
293 rdf:type schema:Organization
294 grid-institutes:grid.411941.8 schema:alternateName Department of Surgery, University Hospital Regensburg, Regensburg, Germany
295 schema:name Department of Surgery, University Hospital Regensburg, Regensburg, Germany
296 rdf:type schema:Organization
297 grid-institutes:grid.467675.1 schema:alternateName Novartis Pharma GmbH, Nürnberg, Germany
298 schema:name Novartis Pharma GmbH, Nürnberg, Germany
299 rdf:type schema:Organization
300 grid-institutes:grid.5253.1 schema:alternateName Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany
301 schema:name Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany
302 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...